StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report released on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
NASDAQ:BLPH opened at $0.01 on Monday. Bellerophon Therapeutics has a one year low of $0.01 and a one year high of $0.02. The company has a market cap of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. The firm’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.03.
Bellerophon Therapeutics Dividend Announcement
The business also recently announced a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were given a dividend of $0.019 per share. This represents a yield of 117.8%. The ex-dividend date was Thursday, December 19th.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- How to Invest in Biotech Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
